These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29858092)

  • 1. Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain.
    Fukuoka M; Takahashi M; Fujita H; Chiyo T; Popiel HA; Watanabe S; Furuya H; Murata M; Wada K; Okada T; Nagai Y; Hohjoh H
    Mol Ther Nucleic Acids; 2018 Jun; 11():79-90. PubMed ID: 29858092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Non-coding RNAs Are Dysregulated in Huntington's Disease Transgenic Mice Independently of the Therapeutic Effects of an Environmental Intervention.
    Dubois C; Kong G; Tran H; Li S; Pang TY; Hannan AJ; Renoir T
    Mol Neurobiol; 2021 Jul; 58(7):3308-3318. PubMed ID: 33675499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells.
    Das E; Jana NR; Bhattacharyya NP
    Biochem Biophys Res Commun; 2013 Jul; 437(2):217-24. PubMed ID: 23796713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
    Ban JJ; Chung JY; Lee M; Im W; Kim M
    Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of miR-9* in the peripheral leukocytes of Huntington's disease patients.
    Chang KH; Wu YR; Chen CM
    Orphanet J Rare Dis; 2017 Dec; 12(1):185. PubMed ID: 29258536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAX Provides Neuroprotection for Huntington's Disease Via Modulating a Novel Subset of MicroRNAs.
    Weng YT; Chen HM; Chien T; Chiu FL; Kuo HC; Chern Y
    Mov Disord; 2022 Oct; 37(10):2008-2020. PubMed ID: 35997316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widespread alterations in microRNA biogenesis in human Huntington's disease putamen.
    Petry S; Keraudren R; Nateghi B; Loiselle A; Pircs K; Jakobsson J; Sephton C; Langlois M; St-Amour I; Hébert SS
    Acta Neuropathol Commun; 2022 Jul; 10(1):106. PubMed ID: 35869509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.
    Hoss AG; Labadorf A; Latourelle JC; Kartha VK; Hadzi TC; Gusella JF; MacDonald ME; Chen JF; Akbarian S; Weng Z; Vonsattel JP; Myers RH
    BMC Med Genomics; 2015 Mar; 8():10. PubMed ID: 25889241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosome-Based Delivery of miR-124 in a Huntington's Disease Model.
    Lee ST; Im W; Ban JJ; Lee M; Jung KH; Lee SK; Chu K; Kim M
    J Mov Disord; 2017 Jan; 10(1):45-52. PubMed ID: 28122430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment.
    Díez-Planelles C; Sánchez-Lozano P; Crespo MC; Gil-Zamorano J; Ribacoba R; González N; Suárez E; Martínez-Descals A; Martínez-Camblor P; Álvarez V; Martín-Hernández R; Huerta-Ruíz I; González-García I; Cosgaya JM; Visioli F; Dávalos A; Iglesias-Gutiérrez E; Tomás-Zapico C
    Pharmacol Res; 2016 Jun; 108():102-110. PubMed ID: 27155059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-34a-5p as molecular hub of pathomechanisms in Huntington's disease.
    Hart M; Diener C; Lunkes L; Rheinheimer S; Krammes L; Keller A; Meese E
    Mol Med; 2023 Apr; 29(1):43. PubMed ID: 37013480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
    Sinha M; Ghose J; Bhattarcharyya NP
    RNA Biol; 2011; 8(6):1005-21. PubMed ID: 22048026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-128a dysregulation in transgenic Huntington's disease monkeys.
    Kocerha J; Xu Y; Prucha MS; Zhao D; Chan AW
    Mol Brain; 2014 Jun; 7():46. PubMed ID: 24929669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.